GPT and metabolic dysfunction-associated steatotic liver disease: If future studies in the diabetic population consider including NAFLD outcomes (e.g., serum AST/ALT, imaging, biopsy) when feasible, this would greatly add to the literature and facilitate the formation of evidence-based guidelines.